Article
 

HartungDanielPharmacyChangesLongActingBetaAgonistUtilization(Figure3).jpg

Public Deposited

Downloadable Content

Download image
https://ir.library.oregonstate.edu/concern/articles/qn59q5640

Descriptions

Attribute NameValues
Creator
Abstract
  • PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data from the state of Oregon Medicaid program we performed an interrupted time series regression to evaluate changes in the trend in new LABA prescriptions before and after the FDA’s 2010 advisory. Trends in incident fills were examined among those with and without an asthma diagnosis code, prior respiratory controller medication use, and by age. FINDINGS: Of the 8646 study patients, 53% had a diagnosis of asthma, 21% of patients had no respiratory diagnosis, and 32% did not use a respiratory controller medication in the recent past. The trend in new LABA prescriptions declined by 0.09 new starts per 10,000 patients per month (95% confidence interval [CI] -0.19 to -0.01) following the FDA’s advisory. Among those with a diagnosis of asthma, there was an immediate drop of 0.48 (95% CI -0.93 to -0.03) and a 0.10 (95% CI -0.13 to -0.06) decline in the monthly rate of new starts per 10,000 patients. Immediately following the FDA’s advisory we observed a statistically significant 4.7% increase (95% CI 0.8% to 8.7%) in the proportion of new LABA starts with history of previous respiratory controller medication use. Utilization of LABAs did not change in those without a diagnosis of asthma. IMPLICATIONS: The FDA’s 2010 advisory was associated with modest reductions in LABA utilization overall and in ways highlighted in their recommendations.
  • Keywords: United States Food and Drug Administration, Utilization, Medicaid, Adrenergic beta2-agonists (adrenergic β₂-agonists)
  • Keywords: United States Food and Drug Administration, Utilization, Medicaid, Adrenergic beta2-agonists (adrenergic β₂-agonists)
Rights Statement

Relationships

Parents:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details HartungDanielPharmacyChangesLongActingBetaAgonistUtilization_Figure3_.jpg 2017-07-26 Public Download